Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 3/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | SCD | O00767 | 1/20 | 0.35 |
| ▸ | TNKS | O95271 | 2/20 | 0.35 |
| ▸ | CCR3 | P51677 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30450183 | 1.00 | MEN1 (0.43) | MEN1ALDH1A1MAPTPKMALOX15 | |
| Hydrochloric Acid SCHEMBL30508276 | 0.98 | MEN1 (0.42) | MEN1ALDH1A1MAPTPKMALOX15 | |
| SCHEMBL30508337 | 0.93 | PRMT5 (0.40) | MEN1ALDH1A1MAPTPKMALOX15 | |
| SCHEMBL30508240 | 0.93 | PRMT5 (0.40) | MEN1ALDH1A1MAPTPKMALOX15 | |
| SCHEMBL13468 | 0.91 | HDAC8 (0.39) | GPR119HDAC8PIK3CDSCDTNKS | |
| SCHEMBL19703386 | 0.90 | MEN1 (0.42) | MEN1ALDH1A1MAPTPKMALOX15 | |
| SCHEMBL31757809 | 0.90 | MEN1 (0.42) | MEN1ALDH1A1MAPTPKMALOX15 | |
| Trifluoroacetic Acid SCHEMBL26683826 | 0.88 | HDAC8 (0.41) | GPR119HDAC8 | |
| SCHEMBL25045382 | 0.88 | HTR7 (0.39) | GPR119HDAC8PIK3CDSCDTNKS | |
| SCHEMBL17678127 | 0.88 | PDE9A (0.38) | GPR119HDAC8PIK3CDSCDTNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146035-A1 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | DONG-A ST CO., LTD. (KR) | 2026-05-28 | — | — | US | disclosed |
| EP-4605395-A2 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | Dong-A ST Co., Ltd. (KR) | 2025-08-27 | — | — | EP | disclosed |
| WO-2024084448-A2 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | DONG-A ST CO., LTD. (KR) | 2024-04-25 | — | — | WO | disclosed |
| CN-116478145-B | ALK2 kinase inhibitors | 杭州邦顺制药有限公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| WO-2023198114-A1 | ALK2 KINASE INHIBITOR | 杭州邦顺制药有限公司 | 2023-10-19 | — | — | WO | disclosed |
| CN-116478145-A | ALK2 kinase inhibitors | 杭州邦顺制药有限公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-2837623-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2015-02-18 | — | — | EP | disclosed |
| WO-2012086735-A1 | CONDENSED HETEROCYCLIC COMPOUND | 大正製薬株式会社 (JP) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146035-A1 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | AXL, ERBB2, ERBB3 | MEN1 2419/4885ALDH1A1 2378/4885MAPT 3785/4885 |
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | RARA, RARG, RARB | MEN1 153/4885ALDH1A1 72/4885MAPT 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.